Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Recommendation of “Hold” by Brokerages

Definitive Healthcare Corp. (NASDAQ:DHGet Rating) has been given a consensus rating of “Hold” by the fourteen research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $37.00.

DH has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft lifted their price target on Definitive Healthcare from $21.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, April 5th. Canaccord Genuity Group raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Thursday, February 24th. Credit Suisse Group lowered their price objective on shares of Definitive Healthcare from $30.00 to $24.00 and set a “neutral” rating for the company in a research note on Thursday, February 24th. Canaccord Genuity Group raised Definitive Healthcare from a “hold” rating to a “buy” rating and cut their target price for the stock from $46.00 to $28.00 in a research report on Thursday, February 24th. Finally, Zacks Investment Research downgraded Definitive Healthcare from a “hold” rating to a “sell” rating in a research report on Monday, April 18th.

NASDAQ:DH opened at $24.35 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.77 and a quick ratio of 3.77. The firm has a 50 day simple moving average of $23.38 and a 200-day simple moving average of $27.59. Definitive Healthcare has a 1-year low of $18.15 and a 1-year high of $50.30.

Definitive Healthcare (NASDAQ:DHGet Rating) last issued its quarterly earnings results on Wednesday, February 23rd. The company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.02. The business had revenue of $46.31 million during the quarter, compared to analyst estimates of $44.78 million. As a group, research analysts expect that Definitive Healthcare will post 0.11 EPS for the current year.

In other news, CFO Richard Douglas Booth acquired 2,374 shares of the firm’s stock in a transaction on Thursday, March 3rd. The stock was bought at an average cost of $21.06 per share, with a total value of $49,996.44. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Advisor Group Holdings Inc. bought a new stake in shares of Definitive Healthcare in the 3rd quarter worth about $26,000. Fifth Third Bancorp increased its holdings in Definitive Healthcare by 78.5% in the first quarter. Fifth Third Bancorp now owns 1,185 shares of the company’s stock valued at $29,000 after buying an additional 521 shares during the last quarter. Legal & General Group Plc acquired a new stake in Definitive Healthcare during the fourth quarter valued at approximately $29,000. Hardy Reed LLC bought a new position in Definitive Healthcare during the 1st quarter worth approximately $76,000. Finally, Steph & Co. acquired a new position in shares of Definitive Healthcare in the 4th quarter worth approximately $88,000. 97.34% of the stock is currently owned by institutional investors.

Definitive Healthcare Company Profile (Get Rating)

Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution.

Featured Articles

Analyst Recommendations for Definitive Healthcare (NASDAQ:DH)

Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with's FREE daily email newsletter.